This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Companies in this article
GlaxoSmithKline (GSK) and Genmab A/S (Copenhagen:GEN); Following the 1st July announcement by GSK and Genmab of an amendment to the collaborative agreement for ofatumumab in which GSK assumed development responsibility for autoimmune indications, GSK and Genmab announced today plans to refocus the development program of ofatumumab in autoimmune indications.
This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.